Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274548 | 0.94 | RAB9A (0.48) | NOTUMRAB9ATSHRRBP4MEN1 | |
| SCHEMBL767279 | 0.88 | ALDH1A1 (0.43) | RAB9ATSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL630858 | 0.80 | RBP4 (0.68) | NOTUMTSHRRBP4 | |
| SCHEMBL10274113 | 0.77 | AKR1C3 (0.45) | TSHRRBP4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL631908 | 0.73 | RBP4 (0.73) | NOTUMRBP4MEN1KMT2AL3MBTL1 | |
| SCHEMBL10274111 | 0.73 | RBP4 (0.50) | RAB9ATSHRRBP4MEN1KMT2A | |
| SCHEMBL767464 | 0.72 | RAB9A (0.39) | RAB9ATSHRRBP4KMT2AMAPT | |
| SCHEMBL10274552 | 0.70 | GAA (0.43) | RAB9ARBP4MEN1KMT2AMAPT | |
| SCHEMBL767083 | 0.70 | RBP4 (0.44) | RAB9ATSHRRBP4MEN1KMT2A | |
| SCHEMBL766972 | 0.69 | RBP4 (0.43) | TSHRRBP4MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | NOTUM 2302/4885RAB9A 4205/4885TSHR 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.